Register Free
Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Cardiology / Cardiovascular
FORWARD CAD IDE Study
Shockwave lithotripsy catheter safely and effectively treats hard calcium buildup in coronary arteries before stent placement.
27 May 2026 NCT06662500
active not recruiting Phase III Rheumatology
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
Bimekizumab compared to risankizumab for treating active psoriatic arthritis over 16 weeks.
27 May 2026 NCT06624228
● Recruiting Respiratory / COPD / Asthma
Electrical Impedance Tomography & Selective Stimulation of Vagus Nerve
Researchers will map which parts of the vagus nerve control specific organs using selective stimulation and imaging during vagal nerve stimulator surgery.
27 May 2026 NCT05664854
● Recruiting Phase III
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington’s Disease
A trial testing whether votoplam slows Huntington's disease progression in early symptomatic patients compared with placebo.
27 May 2026 NCT07326709
● Recruiting Phase III
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
A trial testing whether nipocalimab injection safely prevents severe low platelet counts in babies of at-risk pregnant women.
27 May 2026 NCT06533098
active not recruiting Phase III
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
Romosozumab versus bisphosphonates for reducing fractures and improving bone density in children with osteogenesis imperfecta over 12 months.
27 May 2026 NCT05972551
active not recruiting
DiamondTemp Global Registry
A worldwide study tracking how the DiamondTemp device performs in real-world patient care across multiple hospitals.
27 May 2026 NCT04735016
● Recruiting Phase I Oncology
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
What is being tested: [177Lu]Lu-NeoB, a novel radioligand therapeutic targeting GRPR-positive tumours, combined with capecitabine chemotherapy in a dose-escalation study to establish safe and…
27 May 2026 NCT06247995
● Recruiting Phase I Oncology
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
What is being tested: Zanzalintinib (a novel therapeutic agent) is being evaluated as monotherapy and in combination with immune checkpoint inhibitors (nivolumab ± ipilimumab)…
27 May 2026 NCT05176483
● Recruiting Phase III Oncology
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn’s Disease
What is being tested: The efficacy of dual targeted therapy combining vedolizumab (α4β7 integrin inhibitor) and upadacitinib (JAK inhibitor) versus vedolizumab monotherapy in reducing…
27 May 2026 NCT06227910
● Recruiting Phase I Oncology
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
What is being tested: TUB-040, a novel NaPi2b antibody-drug conjugate (ADC), is being investigated in a first-in-human trial to establish safety, tolerability, pharmacokinetics, and…
27 May 2026 NCT06303505
● Recruiting Phase III Oncology
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Treatment being tested: A fixed-duration combination of sonrotoclax (a novel BCL2 inhibitor) plus zanubrutinib (a Bruton tyrosine kinase inhibitor) compared to the established venetoclax…
27 May 2026 NCT07277231
● Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Study tracking disease progression and treatment outcomes in patients with ATTR amyloidosis, including the new drug eplontersen.
26 May 2026 NCT06465810
active not recruiting Phase III Oncology
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Testing whether adding pembrolizumab and olaparib to chemotherapy and radiation improves survival in early-stage small cell lung cancer.
26 May 2026 NCT04624204
● Recruiting
EXtubation Related Complications – the EXTUBE Study (EXTUBE)
EXTUBE tracked complications after removing breathing tubes in anesthetised and critically ill patients across multiple hospitals worldwide.
26 May 2026 NCT06442930
● Recruiting Phase II Mental Health / Psychiatry
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
BPL-003 Trial Summary Intranasal BPL-003 with psychological support tested for safety and effectiveness in treatment-resistant depression, used alone or with SSRIs.
26 May 2026 NCT05660642
active not recruiting Oncology
Improving Uptake of Bowel Cancer Screening Among South Asian Adults in Bradford
Study tests whether culturally tailored screening materials and a biodegradable collection tool increase bowel cancer screening uptake among South Asian adults in Bradford.
26 May 2026 NCT07376694
● Recruiting Phase I / Phase II
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
ETX101 gene therapy trial testing safety and effectiveness in infants and children with Dravet syndrome.
26 May 2026 NCT05419492
active not recruiting Phase III Oncology
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
GLORIOSA Trial Summary Adding mirvetuximab soravtansine to bevacizumab improves outcomes in platinum-sensitive ovarian cancer with high folate receptor expression.
26 May 2026 NCT05445778
● Recruiting Phase I Cardiology / Cardiovascular
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
Drug being tested: CTX310 is undergoing Phase 1 evaluation in a single-arm, open-label design with ascending doses to establish safety and tolerability in adults…
26 May 2026 NCT07491172
● Recruiting Phase III Oncology
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Treatment being tested: Trastuzumab deruxtecan (T-DXd), a HER2-targeted antibody-drug conjugate, combined with bevacizumab versus bevacizumab alone as first-line maintenance therapy in patients with HER2-expressing…
26 May 2026 NCT06819007
● Recruiting Phase II Oncology
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
What is being tested: Volrustomig, a novel anti-cancer agent, is being evaluated both as a standalone treatment and combined with existing anti-cancer drugs in…
26 May 2026 NCT06535607
● Recruiting Phase III Oncology
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
What is being tested: Dostarlimab (a PD-1 checkpoint inhibitor) versus placebo as maintenance therapy following chemoradiation in patients with locally advanced, unresectable head and…
26 May 2026 NCT06256588
● Recruiting Women's Health
Whole-Body Cryotherapy as a Non-Pharmacological Treatment to Reduce Chronic Pelvic Pain and Improve Quality of Life in People With Endometriosis
Trial tests whether brief extreme cold exposure reduces endometriosis pain and improves quality of life in thirty participants.
22 May 2026 NCT07603960
active not recruiting Phase III
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
A gene therapy trial testing whether a single infusion can slow muscle weakness in boys with Duchenne muscular dystrophy.
22 May 2026 NCT05881408
● Recruiting Phase II
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Trial testing new drug LY4005130 versus placebo for severe hair loss, measuring effectiveness, safety, and how body processes drug.
22 May 2026 NCT07533006
● Recruiting Phase II
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves’ Disease
A trial testing whether rilzabrutinib improves Graves' disease symptoms and safety over 16 weeks in two dose groups.
22 May 2026 NCT06984627
active not recruiting Phase III Oncology
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Adding CGT9486 to sunitinib compared to sunitinib alone for gastrointestinal stromal tumour patients who've failed or are intolerant to imatinib.
22 May 2026 NCT05208047
active not recruiting Phase III Diabetes / Metabolic
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ – CVOT)
Survodutide injection reduces cardiovascular events in overweight or obese adults with heart or kidney disease compared to placebo.
22 May 2026 NCT06077864
● Recruiting Respiratory / COPD / Asthma
The CATALINA Study
What is being tested: CATALINA is collecting standardised longitudinal clinical data and biological samples from COPD patients across multiple European centres to identify patterns…
22 May 2026 NCT05008081
● Recruiting Phase I Oncology
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
What is being tested: OKN4395, a novel investigational drug, is being evaluated as monotherapy and in combination with pembrolizumab (an established PD-1 checkpoint inhibitor)…
22 May 2026 NCT06789172
● Recruiting Phase I Oncology
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
Drug being tested: DS9051b, a first-in-human (FIH) investigational agent, is being evaluated for safety, tolerability, and early efficacy signals in two aggressive malignancies: advanced/metastatic…
22 May 2026 NCT07189403
● Recruiting Phase I Oncology
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Treatment being tested: Patritumab deruxtecan (MK-1022), a HER2-targeted antibody-drug conjugate, either alone or in combination with other anticancer agents in patients with HER2-positive unresectable…
22 May 2026 NCT06686394
● Recruiting Phase II Oncology
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
Treatment Being Tested: Datopotamab deruxtecan (Dato-DXd) monotherapy versus Dato-DXd combined with the immunotherapy agent durvalumab in patients with PD-L1-negative metastatic triple-negative breast cancer (TNBC).…
22 May 2026 NCT06954480
● Recruiting Phase III Oncology
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
What is being tested: Tabelecleucel, an EBV-specific T-cell immunotherapy, is being evaluated for treating EBV-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in solid organ and…
22 May 2026 NCT03394365
● Recruiting Cardiology / Cardiovascular
Mechanism of Chronic Pain in Patients With IBD
What is being tested: This trial investigates the underlying biological mechanisms causing chronic abdominal pain in IBD patients, particularly why pain persists even during…
22 May 2026 NCT04995224
● Recruiting Cardiology / Cardiovascular
Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial
What is being tested: The PEACH trial uses positron emission tomography (PET) imaging to evaluate whether Camzyos (mavacamten), a cardiac myosin inhibitor, reduces myocardial…
22 May 2026 NCT07120776
● Recruiting Phase I Cardiology / Cardiovascular
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
What is being tested: Belantamab, an unconjugated antibody targeting BCMA (B-cell maturation antigen), is being evaluated as both a monotherapy and in combination regimens…
22 May 2026 NCT05714839
● Recruiting Cardiology / Cardiovascular
Biofeedback Intervention for Paroxysmal Atrial Fibrillation
What is being tested: A biofeedback intervention system designed to enable daily monitoring of atrial fibrillation (AF) episodes and physical activity levels in patients…
22 May 2026 NCT07454317
● Recruiting Phase I Oncology
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Drug Being Tested: INBRX-109 is a first-in-human recombinant humanized tetravalent antibody targeting death receptor 5 (DR5), designed to trigger apoptosis in cancer cells through…
22 May 2026 NCT03715933
active not recruiting Cardiology / Cardiovascular
FARAPULSE Workflow Assessment Registry
Registry examining clinical workflows and outcomes when using pulsed field ablation to treat atrial fibrillation in routine practice settings.
20 May 2026 NCT06656884
active not recruiting Phase I Oncology
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Early-stage safety and dosage trial of new anti-CCR8 antibody BAY3375968 alone or combined with pembrolizumab in advanced solid tumours.
20 May 2026 NCT05537740
● Recruiting
Assessing the Efficacy of a Song to Improve Body Appreciation Among Young Children
A song about body confidence was tested in 4-6 year-old UK children to see if it improves how they feel about their bodies.
20 May 2026 NCT07586852
active not recruiting Phase II
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Trial comparing two drug combinations for newly diagnosed mantle cell lymphoma, measuring minimal disease status at six months.
20 May 2026 NCT04802590
active not recruiting Oncology
Contrast-Free Magnetic Resonance Imaging for Breast Disease
MRI without contrast dye can accurately diagnose breast cancer in women at risk or with suspected disease.
20 May 2026 NCT05006196
● Recruiting Neurology
The Co-Production and Evaluation of the Computerised Cognitive Assessment for Preclinical Alzheimer’s Disease (CoCoA-PAD)
What is being tested: Development and evaluation of CoCoA-PAD, a computerised cognitive assessment tool designed to identify individuals in the preclinical stages of Alzheimer's…
20 May 2026 NCT07598617
● Recruiting Phase II Respiratory / COPD / Asthma
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
What is being tested: Adagrasib (MRTX849), a KRAS G12C inhibitor, evaluated as monotherapy and combined with pembrolizumab (anti-PD-L1 immunotherapy) in patients with advanced non-small…
20 May 2026 NCT04613596
● Recruiting Phase II Respiratory / COPD / Asthma
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
What is being tested: Adagrasib (MRTX849), a targeted KRAS G12C inhibitor, is being evaluated as monotherapy and in combination with the immunotherapy pembrolizumab in…
20 May 2026 NCT04613596
● Recruiting Phase I Respiratory / COPD / Asthma
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
What is being tested: XTMAB-16, an investigational monoclonal antibody, is being evaluated in a phase 1b/2 study as a potential new treatment for pulmonary…
20 May 2026 NCT05890729
● Recruiting Phase I Respiratory / COPD / Asthma
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
What is being tested: XTMAB-16, a novel therapeutic agent, is being evaluated in a phase 1b/2 study to assess its safety, tolerability, and efficacy…
20 May 2026 NCT05890729